Brief: Simcere Pharmaceutical Says Phase-3 Clinical Study Of Suvemcitug Met Primary Study Endpoint
04/01/2024 24:38
Jan 4 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* PHASE III CLINICAL STUDY OF SUVEMCITUG FOR INJECTION
SUCCESSFULLY MET PRIMARY STUDY ENDPOINT
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660